Can ultrasound improve cancer drug delivery?

The company, Phoenix Solutions AS and the Translational Genomics Research Institute are analysing the use of a technology called Acoustic Cluster Therapy (ACT), an approach that delivers chemotherapy to targeted blood cells. Humanscan Co. Ltd are also participating in the research by developing clinically applicable hardware optimised for ACT.

Speaking on the research, Dr. Per Sontum, CEO of Pheonix Solutions said:

"We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program."

Dr. Haiyong Han, head of the Basic Research Unit in TGen’s programme also commented:

"We are pleased that this research program has become a reality and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising.”

Humanscan CEO Sungmin Rhim also said:

"We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development."